EORTC QLQ-C30
The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.
Source record
Citations copied verbatim from the method’s source record. No claim-level verification is inferred from them.
- Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376. · DOI 10.1093/jnci/85.5.365
- Fayers, P. M., & Bottomley, A. (2001). Quality of life research within the EORTC-the EORTC QLQ-C30. European Journal of Cancer, 38(4), 427-431. · DOI 10.1016/s0959-8049(01)00448-8
- Cella, D. (1998). The Functional Assessment of Cancer Therapy Scale: Development and validation. Journal of Clin Oncol, 11(3), 570-579. · URL
Curated claims
Claims persisted in the evidence ledger, each with its own assessment.
This view does not invent a claim assessment when the ledger has none.
Related methods
Generated from the method graph and shown as machine-suggested relations — no evidence claim is inferred.